Glucagon‐Like Peptide‐1 Receptor Agonists and Liver Outcomes in Patients With MASLD and Type 2 Diabetes

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 10, 2025

ABSTRACT Background and Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) have demonstrated long‐term liver benefits in patients with metabolic dysfunction‐associated steatotic disease (MASLD) type 2 diabetes (T2D). However, no direct comparison between these therapies has been conducted. This study aimed to compare major adverse outcomes (MALOs) GLP‐1 RAs SGLT2is MASLD T2D. Methods Using the TriNetX Research Network, a multinational multi‐institutional database, we identified adults T2D who received their first prescription for either RA or an SGLT2i January 2010 June 2023. We conducted propensity score‐matched (PSM) cohort comparing new users of SGLT2is. The primary outcome was risk MALOs, composite endpoint consisting decompensated cirrhosis events, hepatocellular carcinoma, transplantation. Secondary included all‐cause mortality individual components outcome. Results 15,176 pairs treated SGLT2i. adjusted hazard ratio (HR) MALO associated relative 0.84 (95% confidence interval [CI]: 0.73–0.97; incidence rate: 88.9 versus 105.3 events per 10,000 person‐years), primarily driven by reduction (adjusted HR: 0.83, 95% CI: 0.71–0.96). were lower 0.84, 0.75–0.94). Conclusion are better compared

Language: Английский

---

Impact of GLP‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 31, 2025

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promise in reducing alcohol consumption, but their impact on clinical outcomes patients with use disorder (AUD) remains unclear. We investigated the association between GLP-1RAs and development progression of alcohol-related liver disease (ArLD) AUD. Using TriNetX Research Network, we conducted two retrospective cohort studies comparing versus dipeptidyl peptidase-4 inhibitors (DPP-4is) type 2 diabetes. The first included AUD without ArLD (n = 7132 after propensity score matching), while second comprised established 1896 matching). Primary were incident hepatic decompensation cohort. In (median follow-up: 63.2 months), GLP-1RA users showed significantly lower risks developing compared to DPP-4i (incidence rate: 6.0 vs. 8.7 per 1000 person-years; HR: 0.62, 95% CI: 0.44-0.87, p 0.006). also associated reduced all-cause mortality (HR: 0.53, < 0.001). 28.2 demonstrated 39.5 51.4 0.66, 0.51-0.85, 0.001) users. progressing AUD, suggesting potential therapeutic benefits this population.

Language: Английский

---

Cold atmospheric plasma control metabolic syndromes via targeting fat mass and obesity-associated protein

Pharmacological Research, Journal Year: 2025, Volume and Issue: unknown, P. 107720 - 107720

Published: March 1, 2025

Both obesity and metabolic disorders are global medical problems. Driven by prolonged inflammation, increases the risk of developing syndromes such as fatty liver, diabetes, cardiovascular diseases cancers. The fat mass obesity-associated protein (FTO) is an m6A demethylase, elevated activity which known to promote pathogenesis many disorders, leading establishment various FTO inhibitors. By combing through intrinsic connections among four primary problems, we attribute their shared pathological cause inflammation. reviewing roles in promoting these current status existing inhibitors treating syndromes, underpinned paramount potential resolving clinical issues targeting urgent need establishing novel with maximized efficacy minimized side effect. Cold atmospheric plasma (CAP) fourth state matter demonstrated associated chronic introducing characteristics CAP, proposed it a possible solution unresolved given its anti-inflammation feature safety. We also emphasized intensive investigations exploring feasibility using CAP that might function FTO.

Language: Английский

---

Editorial: Beyond Clinical Trials—Real‐World Data Suggest Usefulness of GLP‐1 RAs in MASLD Treatment. Authors' Reply

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 28, 2025

Language: Английский

---